<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282697</url>
  </required_header>
  <id_info>
    <org_study_id>4791</org_study_id>
    <nct_id>NCT01282697</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors</brief_title>
  <acronym>RAPIRI</acronym>
  <official_title>Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapeutic solutions to treat solid tumors that are resistant to conventional treatments are
      now limited. Laboratory data in animals (on pediatric tumors such as brain tumors, sarcomas
      and neuroblastomas) have shown that the combination of irinotecan (HIF1alpha inhibitor) and
      rapamycin (mTOR inhibitor) allowed to block development of blood vessels in the tumor and
      could, in some cases, stop its progression. This drug combination has already been tested in
      adult patients with refractory tumors and seems to give encouraging results with
      stabilization of the tumor. The dose and toxicity of irinotecan and rapamycin are known when
      these drugs are administered separately and in a context different from that of refractory
      tumors. RAPIRI is a phase I clinical trial whose principal objectives are to determine the
      maximum dose at which these two molecules may be administered and to assess the safety of
      this new combination of drugs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of irinotecan and rapamycin combination in children with refractory solid tumors.</measure>
    <time_frame>28 days</time_frame>
    <description>The Dose-Limiting Toxicity (DLT) of the drug combination is determined during the first cycle (J1 to J28) of treatment. MTD will be defined as the dose level immediately below the dose level at which 2 patients in a cohort of 3 to 6 patients will have experienced a DLT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the pharmacokinetics of rapamycin and irinotecan during the first cycle of treatment.</measure>
    <time_frame>Day1 + day8</time_frame>
    <description>Pharmacokinetic parameters for rapamycin will be evaluated at days 1 and 8 of the first cycle of treatment. Pharmacokinetic parameters for irinotecan will be evaluated at day 1 of the first cycle of treatment. Pharmacokinetic profile will be modelized for each patient.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Refractory Solid Tumors in Children</condition>
  <arm_group>
    <arm_group_label>rapamycin+irinotecan at a given dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined administration of irinotecan and rapamycin</intervention_name>
    <description>This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.</description>
    <arm_group_label>rapamycin+irinotecan at a given dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 1 year old and =&lt; 21 years old;

          -  Refractory solid tumors, histologically proven at diagnosis (no additional biopsy
             needs to be performed for the purpose of the study);

          -  Relapsed or refractory solid tumors after standard treatment or phase II, III-IV
             clinical trials treatment have failed;

          -  Karnofsky or Lansky status &gt;= 70%;

          -  Life expectancy &gt;= 8 weeks;

          -  No chemotherapy / radiotherapy within 4 weeks before entry into the study;

          -  Adequate biological parameters :

               -  Absolute neutrophil count &gt;= 1.0 x 109/L;

               -  Platelet count &gt;= 100 x 109/L;

               -  Hemoglobin &gt;= 8 mg/dL;

               -  Total bilirubine =&lt; 1.5 ULN;

               -  Transaminases =&lt; 2.5 ULN (=&lt; 5 ULN in case of liver metastases);

               -  Creatinine clearance (Cockroft) &gt;= 70 mL/min/1.73 m2;

               -  Normal coagulation profile with prothrombin &gt;= 70%, TCA =&lt; 35 and fibrinogen &gt;= 2
                  g/L;

          -  Patients with 1 to 3 previous therapeutic lines are eligible;

          -  No current grade &gt;= 2 organ toxicity based on NCI-CTCAE version 3.0;

          -  All patients with reproductive potential must have an effective method of birth
             control while on study;

          -  Negative pregnancy test in females when indicated;

          -  Informed written consent signed by patients or their parents or legal guardians;

          -  Patient who was informed of the results of prior medical consultation;

          -  Patient having a social insurance.

        Exclusion Criteria:

          -  Patient with a constitutional anomaly of coagulation and/or of hemostasis (type
             hemophilia, von Willebrand disease, congenital clotting factor deficit, platelet
             disorder), exposing them to increased risk of bleeding;

          -  Pre-treatment with a mTOR inhibitor;

          -  Other simultaneous malignancy;

          -  Concurrent administration of any other anti-tumour therapy;

          -  Known hypersensitivity or contraindication to study drugs or ingredients;

          -  Severe concomitant disease (e.g. infection disease);

          -  Patient unable for medical follow-up;

          -  Pregnancy and/or lactation;

          -  Patient included in another clinical drug trial;

          -  Patient taking drugs interfering with pharmacology of rapamycin and/or irinotecan
             (e.g. drugs interfering with CYP3A4);

          -  Patient under judicial protection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
    <phone>33(0)388128091</phone>
    <email>Natacha.entz-werle@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erwan PENCREACH, PharmD, PhD</last_name>
    <phone>33(0)388127179</phone>
    <email>Erwan.pencreach@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital des Enfants - Groupe Hospitalier Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves PEREL, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yves PEREL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre LEBLOND, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre LEBLOND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Hémato-Oncologie Pédiatrique (IHOP)</name>
      <address>
        <city>Lyon</city>
        <zip>67008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier FRAPPAZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Didier FRAPPAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas ANDRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas ANDRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mère-Enfants</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadège CORRADINI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nadège CORRADINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle AERTS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle AERTS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Natacha ENTZ-WERLE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hervé RUBIE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hervé RUBIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birgit GEOERGER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Birgit GEOERGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Christine GEILLER</name_title>
    <organization>Direction de la Recherche Clinique et des Innovations - Hôpitaux Universitaires de Strasbourg</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

